Participants: ≥18 years, active non-infectious intermediate, posterior or panuveitic uveitis, despite being on prednisone (10-60mg/day) or an equivalent glucocorticoid for ≥2 weeks
Intervention:
Group 1: Adalimumab (80mg loading dose then 40mg every 2 weeks)
Group 2: Placebo
Both groups received prednisone burst followed by tapering of prednisone over 15 weeks.
Source Archive